Brazil: Update On Brazil's Pharma Patent Landscape

Brazil is the eighth largest pharmaceutical market in terms of revenue and Latin America's largest markets. The consumption of drugs in the retail market represents about 70% of the pharmaceutical industry. Over the past 4 years, there has been a growth of 45% of drugs sold by pharmacies. According to statistics reported by pharmaceutical market reports, sales in the pharmaceutical market at the retail level in Brazil have jumped from BRL28.7 billion (US$11.2 billion) in 2010 to BRL41.8 billion in 2014 (US$13.5 billion). This represents an increase of 45.6% during this period. In 2014, sales in the retail Brazilian market grew by 11.4% over the BRL37.5 billion sold in 2013.

However, recently, the market has undergone some changes. Originator drugs, which accounted for 44% of sales in value terms in 2010, declined to 39% in 2014. In the interim, generics and 'similares' (branded copies of off-patent drugs) have gained market share, climbing from 55% in 2010 to 61% in 2014.

Despite positive performance in the Brazilian pharma market at the retail level, poor economic indicators and economic instability have hampered positive performance in 2015.

The main concern is the high level of inflation in Brazil, which is heading toward double digits according to Brazil's Central Bank forecast.

Additionally, the US dollar attained its highest level in 9 years, reaching BRL4.00 in the last quarter of 2015, which will have implications for the cost of pharmaceutical imports.

The generics sector is one that grows fastest in Brazil. Brazilian government policy is to provide domestic generic production of essential medicines, particularly, vaccines and insulin.

To this end, the government has invested large sums to spur local production, technology and capacity drugs for the treatment of various health problems such as cardiovascular system diseases, anti-infectives, digestive and CNS diseases. As a result, generic drugs have become at least 35% cheaper than the brand named drugs. In 2015, Brazil's generic drug market was valued at approximately BRL17 billion in 2015 [1,2].

Intellectual property issues

There is no doubt that Brazil offers excellent opportunities for foreign drugmakers as market growth for patented drugs is increasing in view of the high number of chronic diseases in Brazil that will generate an ongoing high demand for patented drugs. This scenario will generate opportunities for multinational companies to sell in the Brazilian market. In spite of Brazil's market appeal and the strong presence of the largest innovative drugmakers doing business in Brazil, the United States Trade Representative and the Pharmaceutical Research and Manufacturers of America have each placed Brazil on the 'Priority Watchlist' to date [3,4]. Some key issues of concern and disagreement are patentability standards, data protection, Government price controls and the inappropriate review of pharma patent applications by the National Sanitary Surveillance Agency (ANVISA). In addition, although there is no express bar, in terms of patentability with respect to secondary and polymorph inventions in the Brazilian Intellectual Property (IP) Statute, these inventions have been challenged by ANVISA. To be specific, there is a strong resistance against patenting these inventions from the local pharma industries.

An update on ANVISA's examination

The two-tier substantive examination has completed 15 years ever since Brazil's current Patent Law No. 9279/96 was amended in 2001 to allow ANVISA to conduct a mandatory review/examination on pharmaceutical patent applications before the Brazilian Patent and Trademark Office (PTO)'s substantive examination.

ANVISA Resolution RDC 21/2013 introduced a significant change in the pharma patent examination. Brazilian Resolution RDC 21/2013 [5,6] introduced a new workflow for pharmaceutical patent applications.

With the advent of the new workflow, pharma cases are forwarded directly to the ANVISA for examination supposedly to take into consideration public health issues. ANVISA examiners determine whether or not an application poses risks to public health, and this analysis results in either a grant or denial of 'prior consent' in respect of the pharma applications. Patent cases receiving 'prior consent' will be returned to the PTO for continued prosecution. In practical terms, the applicant receives an unfavorable opinion denying 'prior consent' and has 90 days from receipt of the said opinion to submit a reply. Should the applicant fail or choose not to submit a reply, ANVISA will deny 'prior consent'. All written opinions reporting the conclusion of ANVISA's analysis regarding 'prior consent' (both granting and denial) are published in the Brazilian

Official Gazette. If 'prior consent' of an application is denied by ANVISA, the applicant can file an administrative appeal to the Appeal Board of ANVISA within 60 days of receipt of the opinion. In the event, the appeal is held to be unfounded; the denial of 'prior consent' will be ratified by ANVISA. After ratification of the denial, the application is back to the PTO. At this point, the PTO will essentially 'shelve' the application for an unknown period of time. Presently, no patent application for which 'prior consent' has been denied, under the current workflow, has been shelved by the PTO. It can be asserted that the majority of Brazilian attorneys view the 'shelving' of a patent application without substantive examination by the PTO as a violation of the law and unconstitutional. The rationale is that payment of the examination fee to the Agency (PTO) guarantees an applicant to have its application examined by the Brazilian PTO (which is specifically authorized under the Brazilian Constitution to review patent applications). In the event, an application is 'shelved' by the PTO; the applicant can file an administrative appeal against the shelving. Administrative appeals filed at the Brazilian PTO are analyzed by a board of examiners. If the appeal is rejected, the only available recourse available for the applicant is to file a lawsuit in a Brazilian federal court against ANVISA's intervention in the substantive examination of the pharmaceutical patent application and against the PTO's refusal to examine the application.

Recent statistics show that approximately 20 lawsuits have been brought against ANVISA in connection with its denial of 'prior consent' under the previous workflow (where applications were first examined by the PTO and then sent to ANVISA for examination based on public health issues). In the majority of these lawsuits, the court has reversed ANVISA's denial of 'prior consent'. In these cases, the court has held that ANVISA must limit its review of an applicant's patent application solely to health issues, meaning that if the PTO approved a patent application directed to a pharmaceutical product of process, then a patent should be granted. Court decisions in favor of patentees have been issued in district courts of Brasilia.

Some courts have issued preliminary injunctions ordering ANVISA to grant 'prior approval' of patent applications on the ground that ANVISA did not have the competence to conduct 'patentability' examination.

A recent unexpected decision from the Federal District Court in Rio de Janeiro denied a preliminary injunction and ruled that ANVISA was competent to examine a pharma patent application in terms of patentability requirements. In all likelihood, this decision will be used by ANVISA to assert its legitimacy to examine pharma patent applications and patentees and

Brazilian attorneys will have to be innovative to overrule this decision. Several grounds for court actions against ANVISA exist but the main ones include:

ANVISA examiners have no competence and expertise to examine pharmaceutical patent applications;

ANVISA's mandatory review of pharma cases which results in rejection of certain claims is a discrimination against pharmaceutical inventions and is a clear violation of Article 27.1 of Trade Related Aspects of Intellectual Property (TRIPS) agreement; and the shelving of a pharmaceutical patent application by ANVISA without prior substantive examination by the Brazilian PTO is unconstitutional.

Mailbox patent litigation

Given the huge backlog of patent applications pending examination, patent prosecution in Brazil has been taking much longer than 10 years. This delay can be evidenced by productivity at the Brazilian PTO in 2014. Statistics show that the government agency granted a little over 2000 patents and that approximately 1300 of these granted patents issued with a term of 10 years from the date of grant. This is a clear indication that the prosecution time span exceeded 10 years and consequently the patentee is guaranteed the term established in the sole paragraph of Article 40 of Brazilian Patent Law 9.279/96. Said Article 40 reads as follows: "the term of a patent of invention shall be 20 years and that of a utility model patent shall be 15 years counted from the filing date of the application" [7]. "Sole paragraph – The term shall be no less than 10 years for a patent of invention and 7 years for a utility model patent counted from the date of the grant, except where the BPTO is prevented from carrying out the substantive examination of the application owing to a duly evidenced judicial dispute or for reasons of force majeure." This 10-year term guarantee has, suddenly, spurred controversy, in particular from the local generic industry and non-governmental organizations. The applicability of the sole paragraph of Article 40 to mailbox patents is currently being challenged by the Brazilian PTO and by the Gx industry associations such as ABIFINA at the lower federal trial courts.

The Brazilian PTO has recently filed a large number of court actions aiming revoking several pharmaceutical and agrochemical patents before the Federal Court of Rio de Janeiro.

Actually, all of the patents involved in such court actions are related to pharmaceutical and agrochemical products/processes that belong to the so-called 'mailbox' types (also called black box), in other words, they were filed between 1 January 1995, when the TRIPS agreement came into force, and 14 May 1997, when the new Brazilian IP Law came into force. Note that inventions covering pharmaceutical and agrochemical products/processes were not statutory subject matter prior to the TRIPS and the new law. It is important to highlight that the Brazilian PTO published on 10 September (one day before filing the court actions) a legal opinion from the Attorney General's office asserting that such patents (known as mailbox types – filed between 1 January 1995 and 14 May 1997) must be granted with a 20-year term counted from the filing date (as provided by Article 40 of the Brazilian IP Law), and not with a 10-year term counted from its granting (sole paragraph of Article 40 of the Brazilian IP Law).

In view of the above, considering that all patents involved in these court actions were granted with a 10-year term from the (granting) date of issue, instead of the 20-year term from the filing date, the PTO alleges that such patents were granted in dissonance with the provisions of the Brazilian IP Law. As a result, these patents should be canceled by the Federal Court of Rio de Janeiro. Moreover, based on Article 229, sole paragraph of Law 9279, the PTO has requested the Federal Court to recognize that the patents should not have been granted with the 10-year term and so apply the 20-year term of protection counted from the filing date.

Based on this allegation, ABIFINA and the Brazilian generic industry have fiercely contested the 10-year patent term guarantee in the sole paragraph of Article 40 through a number of different mechanisms. For example, the local chemical industry has lobbied against Article 40 via the 'Patent Reform' Bill (#5402/2013), which is presently being discussed by the Brazilian Congress. The Patent Reform Bill contains a number of antipatent provisions, including one that would eliminate the 10-year minimum patent term. Six court actions were already decided by trial judges against the Brazilian PTO's claim, that is, maintaining the patents in force and reinforcing that their term of protection should be 10 years counted from the grant. In response, the Brazilian PTO has filed appeals on the merits against these decisions at the Federal Court of Appeal arguing that:

  • The delay in granting the 'mailbox' patents was brought about by the aforementioned Provisional Measure of 1999, which has been beneficial for patentees inasmuch as their patents would never have been granted without these specific provisions for 'mailbox' patents;
  • The principle of legitimate expectations is not applicable in the present case since patentees would not be assured that the decision that granted their 'mailbox' patents would not be challenged in the future, since a patent can be declared null at any moment, as provided in the Brazilian IP Law; The purpose of these lawsuits is to modify the patent term of the 'mailbox' patents, and, therefore, the consequences of this change would apply from now on;
  • The principle of legality should prevail in view of the social interest since the grant of a patent with a longer term than the one defined in the law would be detrimental to the general public.

The decisions so far at the appellate level have been favorable for the plaintiff (Brazilian PTO). And the PTO scored successfully 2 × 1 in practically all the cases. Given these results, it can be interpreted that the patentees can still pursue this issue further at the Superior Court.

Brazil's new biodiversity law

Until recently, Provisional Act 2.186/16/01 of 23 August 2001 was the piece of legislation that governed the access to components of Brazilian genetic heritage, and the protection and access to any associated traditional knowledge.

On 20 May 2015, the Brazilian President Dilma Rousseff sanctioned the Biodiversity Law No. 13.123/15, which regulates the access to components of Brazilian genetic heritage, the protection and access to associated traditional knowledge and the sharing of benefits for the preservation and sustained use of Brazilian biodiversity. The main objective of the new law is to facilitate scientific research and economic exploitation involving access to samples of Brazilian genetic heritage [7].

As a result, there is a great expectation that national and international companies, especially those in the pharmaceutical, agricultural and cosmetic fields, will be encouraged to develop new products containing active ingredients from Brazilian biodiversity.

Some of the key changes brought by the new law are as follows:

  • New rules for access to Brazilian genetic heritage made by foreign companies;
  • Legal security for private companies investing resources in Research Development & Innovation – a 'benefit sharing program', which supports communities that provide their traditional knowledge to the industry, and the 'National Sharing Fund' to manage the financial resources received – adoption of the maximum share of 1% of the company's net revenue obtained by selling the final product resulting from the access to a component of Brazilian genetic heritage;
  • A guarantee to free negotiation over the traditional knowledge and an additional 0.5% of the profit to the National Sharing Fund while the product is being sold – profit sharing of 1% with the National Sharing Fund if the traditional knowledge is not identified;
  • Exemption of small companies and suppliers from sharing their profit, since they have less productive capacity. It is important to highlight that the companies and researchers will no longer need prior authorization to start a research project involving an active ingredient from Brazilian biodiversity, but rather simple electronic registration. Based on the provisions of the new Biodiversity Law, an authorization is only required if the company decides to commercialize a product developed from the results obtained in the research.

Clinical trials

The Brazilian ANVISA published a final resolution in February 2015 on new rules to expedite the authorization of clinical trials of medical products in Brazil [8]. This final version of the regulation modifies

Resolution 39-2008 following a public consultation held in 2014, with 641 contributions from the Brazilian clinical research sector. Under the new regulation, ANVISA will have two new deadlines to evaluate the Drug Clinical Development Briefings, which contain the clinical trials applications to be carried out in Brazil:

  • A 90-day period for reviewing international Phase III clinical trials of synthetic medicines: if ANVISA does not reply within the 90-day period, the sponsor may start the clinical research, provided it obtains approval from the responsible ethics review boards.
  • A 180-day period for reviewing local Phase I and II clinical trials: for this group of trials, the clinical research cannot begin until an official ANVISA decision. With the advent of this new regulation, ANVISA aims at expediting the authorization process for starting clinical trials without losing the quality and credibility of the process.

The new regulation seeks to harmonize national legislation with international industry guidelines. This new reform is particularly favorable for the international pharmaceutical industry as a regulation to speed up approval of clinical trials has been the subject of discussions between the agency and industry since 2012. The new regulation aligns with ANVISA's policy of improving the process for pharmaceutical companies to access the Brazilian market. In fact, recently ANVISA introduced new regulations that facilitate some of the internal processes such as marketing authorizations and the process for importing drugs. It is expected that a faster and efficient assessment of clinical trials' applications will attract more international pharmaceutical companies to develop clinical research in the South American country. An important aspect is that since private R&D activities consists mainly in clinical studies, a speedy approval of a clinical study will stimulate investments by foreign pharma companies.

Backlog

Unfortunately, in spite of the fact that the Brazilian PTO have taken steps to increase the number of patent examiners, the situation has not improved for the simple reason that during the last decade, there has been a constant hike in patent filings at the Patent Office.

It is estimated that total patent filings in 2014 were approximately 36,000. As a result, the backlog of patent applications pending substantive examination has continued to increase. The Brazilian PTO's Director, at one point of time, considered launching a program called 'Promoted Withdrawal'. Basically, this program contemplated allowing an applicant to abandon an 'old' pending patent application and refile it as a new application (paper or electronic filing) which would be placed much ahead in the queue for examination. The rationale was to encourage applicants to maintain only those applications that were of real commercial interest. Apparently, this project has not materialized.

Also, the PTO's intention is to add 100 examiners to the existing workforce each year until 2018. This will entail sitting a compulsory examination to qualify as an examiner inasmuch as civil servants must undergo such a procedure to work in a government office. The Director holds that with advent of the new examiners the prosecution and examination of applications will be expedited, thus reducing the backlog. Given the current political and financial turmoils, it is hardly expected that the Brazilian Government will be able to implement and/or materialize any favorable changes to existing IP legislation and policies.

The adoption of Patent Prosecution Highway (PPH) has been discussed for several years but nothing concrete had come out from these prior discussions and/or negotiations. However, in June last year, during the Brazilian President's visit to the USA for a bilateral trade agenda, the USA and Brazil have agreed to sign a letter of intentions whereby the Brazilian PTO would adopt a PPH Pilot Program to streamline the examination of patent applications and ultimately reduce the huge backlog of patent cases. At the outset, the Pilot Program would apply solely to the oil and gas technology area. Since then, a memorandum of understanding has materialized and executed by both parties.

On 5 January 2016, the Brazilian PTO published Resolution 154/2015 establishing the long-awaited guidelines of the PPH Pilot Program between the USPTO, and the Brazilian PTO which could speed up examination of Brazilian applications duly filed and regularly pending in Brazil after a corresponding application from the same family receives notice of allowance from the USPTO.

The Pilot Program will be limited to the first 150 applications. The program was launched on 11 January 2016 and relevant guidelines were made available on the PTO's website. Applicants requesting PPH examination at the Brazilian PTO must file a comparative table of the claims granted by the USPTO and the corresponding pending claims in the Brazilian PTO official files. The duration of the program is up to 2 years, or until 150 applications have been received and processed. It is too early to speculate how much the Pilot Program will benefit applicants who face a 13-year average backlog at the Brazilian PTO.

Similar fast-track initiatives have been adopted for expediting examination of applications relating to green technologies, cancer and HIV, as well as pending applications with at least one infringed claim. Statistics show that a final decision is rendered between 12 and 18 months.

Future perspective

The importance of the Brazilian market is unquestionable and the history of Brazil's initiatives to achieve a decent IP legislation is positive. Brazil was one of the first countries to join the Paris Union Convention and is signatory to most of the major World

IP Treaties. Although Law No. 9.279/96 is fairly a good piece of work, the Brazilian PTO has been labeled inefficient for its bureaucracy and backlog.

The current Patent Law is basically TRIPS compliant with the exception of some provisions which are not harmonized with those of leading legislations or even with TRIPS. The absence of provisions for data exclusivity periods for human pharmaceuticals and Patent Linkage bears weight when pharma companies seek patent protection in Brazil. The additional hurdle imposed by the Brazilian Government to empower ANVISA to conduct a second examination on pharmaceutical applications spurs dissatisfaction for pharma companies doing business in Brazil.

The serious adverse factor, however, is the backlog which has extended for years and years. The situation is chaotic as the backlog stands at approximately 200,000 patent applications pending substantive examination. The effective solution is to hire more patent examiners, which is easier said than done.

The total number is approximately 300 examiners and the goal is to raise this number to a realistic 700.

The PTO has adopted several measures to accelerate the examination of patent applications, namely, on the basis of evidenced infringement, a green patent Pilot Program. In the pharmaceutical arena, there are several situations where an applicant can expedite examination and, recently PPH, between the USA and Brazil, was adopted for patent applications in the oil and gas technology area. The country's logistics and infrastructure problems in the major cities were partially resolved after hosting two mega events, World Cup and Olympics, and as a result investments are expected to increase principally in the pharma, biotech and agrobusinesses.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions